NuCana (NCNA) Stock Rating Lowered by Zacks Investment Research

NuCana (NASDAQ:NCNA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “

A number of other research firms have also recently commented on NCNA. William Blair assumed coverage on NuCana in a research note on Monday, October 23rd. They set an “outperform” rating on the stock. Citigroup assumed coverage on NuCana in a research note on Monday, October 23rd. They set a “buy” rating and a $23.00 target price on the stock. Cowen assumed coverage on NuCana in a research note on Monday, October 23rd. They set an “outperform” rating on the stock. Finally, Jefferies Group assumed coverage on NuCana in a research note on Monday, October 23rd. They set a “buy” rating and a $25.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus price target of $20.67.

NuCana (NASDAQ:NCNA) traded up $0.58 during midday trading on Tuesday, hitting $14.30. The stock had a trading volume of 116,318 shares, compared to its average volume of 55,579. The company has a market cap of $455.95 and a PE ratio of -44.69. NuCana has a 12 month low of $9.32 and a 12 month high of $19.95.

A number of institutional investors have recently made changes to their positions in NCNA. Baillie Gifford & Co. bought a new stake in NuCana in the 3rd quarter valued at about $8,266,000. Sphera Funds Management LTD. bought a new stake in NuCana in the 3rd quarter valued at about $919,000. Citadel Advisors LLC bought a new stake in NuCana in the 3rd quarter valued at about $1,218,000. Alyeska Investment Group L.P. bought a new stake in NuCana in the 3rd quarter valued at about $2,296,000. Finally, Perceptive Advisors LLC bought a new stake in NuCana in the 3rd quarter valued at about $3,674,000. Institutional investors and hedge funds own 22.27% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “NuCana (NCNA) Stock Rating Lowered by Zacks Investment Research” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.thelincolnianonline.com/2018/01/13/nucana-ncna-stock-rating-lowered-by-zacks-investment-research.html.

NuCana Company Profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply